JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
Не применимо
Завершено
NCT06287073
| Заболевание | Kidney Disease, Chronic |
|---|
| Фаза | Не применимо |
|---|
| Спонсор | Boehringer Ingelheim |
|---|
| Статус | Завершено |
|---|
| Участники | 299 участн. |
|---|
| Вмешательство | JARDIANCE® |
|---|
| Дата начала | 29.03.2024 |
|---|
| Дата завершения | 30.04.2025 |
|---|
| Публикация результатов | 23.06.2026 |
|---|
Кратко
The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice. The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.
Number of Participants With Adverse Events (AEs)
Up to 337 days. · Participants
| JARDIANCE® Treated Patients | 46 Participants |
|---|
Number of Participants With Serious Adverse Event (SAEs)
Up to 337 days. · Participants
| JARDIANCE® Treated Patients | 6 Participants |
|---|
Number of Participants With Non-serious Adverse Events
Up to 337 days. · Participants
| JARDIANCE® Treated Patients | 42 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.